Skip to the main content

Medicina Fluminensis, Vol. 46 No. 4, 2010.

Review article

Arterial hypertension

Martina Pavletić Peršić ; Zavod za nefrologiju i dijalizu, Klinika za internu medicinu, Klinički bolnički centar Rijeka
Sretenka Vuksanović-Mikuličić ; Zavod za nefrologiju i dijalizu, Klinika za internu medicinu, Klinički bolnički centar Rijeka
Sanjin Rački ; Zavod za nefrologiju i dijalizu, Klinika za internu medicinu, Klinički bolnički centar Rijeka

Full text: croatian pdf 320 Kb

page 376-389

downloads: 8.099

cite

Abstract

Arterial hypertension is the biggest public health problem in Croatia and abroad.
European countries, including Croatia, have similar epidemiologic data, with significant differences
in comparison to the USA. The level of hypertension control of our patients is very
low (19.4 %), which is why it is necessary to intensify the measures of primary prevention
and treatment. The efficacy of antihypertensive therapy can be improved by simultaneous
and continuous education of both patients and doctors. Professional societies have published
numerous guidelines in the past few years, intended to help us to treat our patients.
Classification of arterial hypertension and the need to introduce therapy according to the
2007 European Society of Hypertension and European Society of Cardiology guidelines is
based on blood pressure values and total cardiovascular risk. Every treatment is based on
correct diet and change in the lifestyle (appropriately dosed moderate daily physical activity,
reduction of body weight, no smoking and moderate consumption of alcohol, as well as a
diet based on fruit, vegetables, white meat, fish and polyunsaturated fatty acids and reduced
intake of salt); this leads to a decrease in the arterial pressure and may consequently
result in reduced incidence of the arterial hypertension (and all the ensuing complications).
Pharmacological therapy includes diuretics, beta blockers, calcium channel blockers, ACE inhibitors
and angiotensin receptor blockers (AT1). In the near future, the offer in our market
should also include aliskiren (direct rennin inhibitor) and eplerenon (selective aldosterone
blocker).

Keywords

arterial hypertension; cardiovascular risk; continuous blood pressure control

Hrčak ID:

63061

URI

https://hrcak.srce.hr/63061

Publication date:

8.12.2010.

Article data in other languages: croatian

Visits: 11.090 *